Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
217 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2014', provides an overview of the Respiratory Syncytial Virus (RSV) Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Respiratory Syncytial Virus (RSV) Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Respiratory Syncytial Virus (RSV) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Respiratory Syncytial Virus (RSV) Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Respiratory Syncytial Virus (RSV) Infections Overview 10 Therapeutics Development 11 Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Overview 11 Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis 12 Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Development by Companies 13 Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Investigation by Universities/Institutes 17 Respiratory Syncytial Virus (RSV) Infections - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 Unknown Stage Products 22 Respiratory Syncytial Virus (RSV) Infections - Products under Development by Companies 23 Respiratory Syncytial Virus (RSV) Infections - Products under Investigation by Universities/Institutes 28 Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development 29 F. Hoffmann-La Roche Ltd. 29 GlaxoSmithKline plc 30 Bavarian Nordic A/S 31 MedImmune, LLC 32 Gilead Sciences, Inc. 33 GenVec, Inc. 34 Merck & Co., Inc. 35 Ablynx NV 36 Emergent BioSolutions Inc. 37 Takeda Pharmaceutical Company Limited 38 Symphogen A/S 39 Celltrion, Inc. 40 Astellas Pharma Inc. 41 Novavax, Inc. 42 Teva Pharmaceutical Industries Limited 43 Crucell N.V. 44 DBV Technologies SA 45 Alnylam Pharmaceuticals, Inc. 46 Panacea Biotec Limited 47 Mucosis B.V. 48 Aridis Pharmaceuticals LLC 49 TechnoVax, Inc. 50 AlphaVax, Inc. 51 Kineta, Inc. 52 MSM Protein Technologies, Inc. 53 Romark Laboratories, L.C. 54 Chimerix, Inc. 55 REPLICor Inc. 56 Microbiotix, Inc. 57 NanoBio Corporation 58 Immunovaccine, Inc. 59 iBio, Inc. 60 Sirnaomics, Inc. 61 Alios BioPharma, Inc. 62 AIMM Therapeutics B.V. 63 3-V Biosciences, Inc. 64 Artificial Cell Technologies, Inc. 65 AmVac AG 66 SelectX Pharmaceuticals, Inc. 67 Spider Biotech 68 Spring Bank Pharmaceuticals, Inc. 69 Navigen Pharmaceuticals, Inc. 70 Agilvax, Inc. 71 Biota Pharmaceuticals, Inc. 72 Humabs BioMed SA 73 Codagenix, Inc. 74 Pulmocide Ltd 75 Respiratory Syncytial Virus (RSV) Infections - Therapeutics Assessment 76 Assessment by Monotherapy Products 76 Assessment by Combination Products 77 Assessment by Target 78 Assessment by Mechanism of Action 81 Assessment by Route of Administration 83 Assessment by Molecule Type 85 Drug Profiles 88 RI-002 - Drug Profile 88 asvasiran sodium - Drug Profile 90 MDT-637 - Drug Profile 92 Respiratory Syncytial Virus Vaccine - Drug Profile 94 ALS-8176 - Drug Profile 96 GS-5806 - Drug Profile 97 MEDI-559 - Drug Profile 98 ALX-0171 - Drug Profile 99 RSV-001 - Drug Profile 100 MEDI-8897 - Drug Profile 101 Monoclonal Antibody for Respiratory Syncytial Virus Infections - Drug Profile 102 GSK-3003891A - Drug Profile 103 GSK-3003892A - Drug Profile 104 GSK-3003893A - Drug Profile 105 GSK-3003895A - Drug Profile 106 GSK-3003896A - Drug Profile 107 GSK-3003898A - Drug Profile 108 GSK-3003899A - Drug Profile 109 MEDI-7510 - Drug Profile 110 respiratory syncytial virus vaccine - Drug Profile 111 Sym-003 - Drug Profile 112 MVA-BN-RSV - Drug Profile 113 Vaccine For RSV - Drug Profile 114 AR-201 - Drug Profile 115 REP-9 - Drug Profile 116 RSV Vaccine - Drug Profile 117 TVX-004 - Drug Profile 118 Respiratory Syncytial Virus Vaccine - Drug Profile 120 Respiratory Syncytial Virus-Virus Like Particle Vaccine - Drug Profile 122 Recombinant Vector Vaccine for Respiratory Syncytial Virus (RSV) Infections - Drug Profile 123 palivizumab biosimilar - Drug Profile 124 Subunit Vaccine For Respiratory Syncytial Virus Infections - Drug Profile 125 Vaccine for Respiratory Syncytial Virus Infections - Drug Profile 126 STP-902 - Drug Profile 128 bordetella pertussis vaccine [BPZE1] - Drug Profile 129 GV-2311 - Drug Profile 130 SynGEM - Drug Profile 131 RSV Vaccine - Drug Profile 132 Innate Immune Agonists - Drug Profile 133 rOAS - Drug Profile 134 AMV-603 - Drug Profile 135 AMV-611 - Drug Profile 136 ALS-8112 - Drug Profile 137 Small Molecules to Target Viral RNA Polymerase for RSV Infections - Drug Profile 138 AMV-601 - Drug Profile 139 AMV-602 - Drug Profile 141 SB-105 - Drug Profile 142 Subunit Vaccine for Respiratory Syncytial Virus - Drug Profile 143 Small Molecule for Viral Diseases - Drug Profile 144 palivizumab biosimilar - Drug Profile 145 RSV-NanoViaSkin - Drug Profile 146 Respiratory Syncytial Virus Vaccine - Drug Profile 147 Small Molecule for Respiratory Syncytial Virus Infections - Drug Profile 148 Monoclonal Antibody for Respiratory Syncytial Virus - Drug Profile 149 RNAi Oligonucleotides for RSV and Viral Respiratory Tract Infections - Drug Profile 150 MAb Against RSV And MPV - Drug Profile 151 Respiratory Syncytial Virus Vaccine - Drug Profile 152 RSV vaccine - Drug Profile 154 influenza and RSV vaccine - Drug Profile 155 Small Molecule Targeting Fatty Acid Synthase for Infectious Disease - Drug Profile 156 Recombinant Granulocyte Macrophage Colony Stimulating Factor - Drug Profile 157 TVX-004IP - Drug Profile 158 MSM-605 - Drug Profile 159 Bispecific Antibodies For RSV - Drug Profile 160 RSV Fusion Inhibitors - Drug Profile 161 Vaccine for RSV Infections - Drug Profile 162 palivizumab biosimilar - Drug Profile 163 MVA-RSV - Drug Profile 165 RSV vaccine - Drug Profile 166 RNAi Oligonucleotide for Respiratory Syncytial Virus Infection - Drug Profile 167 Respiratory Syncytical Virus + Influenza Vaccine - Drug Profile 168 MBX-300 - Drug Profile 169 Respiratory Syncytial Virus Infections Vaccine - Drug Profile 171 Monoclonal Antibody for RSV - Drug Profile 172 Respiratory Syncytial Virus Vaccine - Drug Profile 173 palivizumab biosimilar - Drug Profile 174 Small Molecules for Respiratory Syncitial Virus and Herpes Simplex Virus Infections - Drug Profile 175 Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile 176 Drugs to Inhibit STAT for RSV Infection - Drug Profile 177 RSV vaccine - Drug Profile 178 Respiratory Syncytial Virus Infection Vaccines - Drug Profile 179 Synthetic Peptides for RSV Infection - Drug Profile 180 Small Molecules for Respiratory Syncytial Virus - Drug Profile 181 Small Molecules for Respiratory Syncytial Virus Infections - Drug Profile 182 Small Molecules for RSV Infection - Drug Profile 183 Respiratory Syncytial Virus Vaccine - Drug Profile 184 Respiratory Syncytial Virus (RSV) Infections - Recent Pipeline Updates 185 Respiratory Syncytial Virus (RSV) Infections - Dormant Projects 201 Respiratory Syncytial Virus (RSV) Infections - Discontinued Products 202 Respiratory Syncytial Virus (RSV) Infections - Product Development Milestones 203 Featured News & Press Releases 203 Appendix 210 Methodology 210 Coverage 210 Secondary Research 210 Primary Research 210 Expert Panel Validation 210 Contact Us 211 Disclaimer 211
List of Tables Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H2 2014 17 Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis, H2 2014 18 Number of Products under Development by Companies, H2 2014 20 Number of Products under Development by Companies, H2 2014 (Contd..1) 21 Number of Products under Development by Companies, H2 2014 (Contd..2) 22 Number of Products under Investigation by Universities/Institutes, H2 2014 24 Comparative Analysis by Late Stage Development, H2 2014 25 Comparative Analysis by Clinical Stage Development, H2 2014 26 Comparative Analysis by Early Stage Development, H2 2014 27 Comparative Analysis by Unknown Stage Development, H2 2014 28 Products under Development by Companies, H2 2014 29 Products under Development by Companies, H2 2014 (Contd..1) 30 Products under Development by Companies, H2 2014 (Contd..2) 31 Products under Development by Companies, H2 2014 (Contd..3) 32 Products under Development by Companies, H2 2014 (Contd..4) 33 Products under Investigation by Universities/Institutes, H2 2014 34 Respiratory Syncytial Virus (RSV) Infections - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 35 Respiratory Syncytial Virus (RSV) Infections - Pipeline by GlaxoSmithKline plc, H2 2014 36 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Bavarian Nordic A/S, H2 2014 37 Respiratory Syncytial Virus (RSV) Infections - Pipeline by MedImmune, LLC, H2 2014 38 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Gilead Sciences, Inc., H2 2014 39 Respiratory Syncytial Virus (RSV) Infections - Pipeline by GenVec, Inc., H2 2014 40 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Merck & Co., Inc., H2 2014 41 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Ablynx NV, H2 2014 42 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Emergent BioSolutions Inc., H2 2014 43 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 44 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Symphogen A/S, H2 2014 45 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Celltrion, Inc., H2 2014 46 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Astellas Pharma Inc., H2 2014 47 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Novavax, Inc., H2 2014 48 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 49 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Crucell N.V., H2 2014 50 Respiratory Syncytial Virus (RSV) Infections - Pipeline by DBV Technologies SA, H2 2014 51 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2014 52 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Panacea Biotec Limited, H2 2014 53 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Mucosis B.V., H2 2014 54 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aridis Pharmaceuticals LLC, H2 2014 55 Respiratory Syncytial Virus (RSV) Infections - Pipeline by TechnoVax, Inc., H2 2014 56 Respiratory Syncytial Virus (RSV) Infections - Pipeline by AlphaVax, Inc., H2 2014 57 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Kineta, Inc., H2 2014 58 Respiratory Syncytial Virus (RSV) Infections - Pipeline by MSM Protein Technologies, Inc., H2 2014 59 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Romark Laboratories, L.C., H2 2014 60 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Chimerix, Inc., H2 2014 61 Respiratory Syncytial Virus (RSV) Infections - Pipeline by REPLICor Inc., H2 2014 62 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Microbiotix, Inc., H2 2014 63 Respiratory Syncytial Virus (RSV) Infections - Pipeline by NanoBio Corporation, H2 2014 64 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Immunovaccine, Inc., H2 2014 65 Respiratory Syncytial Virus (RSV) Infections - Pipeline by iBio, Inc., H2 2014 66 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Sirnaomics, Inc., H2 2014 67 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Alios BioPharma, Inc., H2 2014 68 Respiratory Syncytial Virus (RSV) Infections - Pipeline by AIMM Therapeutics B.V., H2 2014 69 Respiratory Syncytial Virus (RSV) Infections - Pipeline by 3-V Biosciences, Inc., H2 2014 70 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Artificial Cell Technologies, Inc., H2 2014 71 Respiratory Syncytial Virus (RSV) Infections - Pipeline by AmVac AG, H2 2014 72 Respiratory Syncytial Virus (RSV) Infections - Pipeline by SelectX Pharmaceuticals, Inc., H2 2014 73 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Spider Biotech, H2 2014 74 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2014 75 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Navigen Pharmaceuticals, Inc., H2 2014 76 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Agilvax, Inc., H2 2014 77 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Biota Pharmaceuticals, Inc., H2 2014 78 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Humabs BioMed SA, H2 2014 79 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Codagenix, Inc., H2 2014 80 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Pulmocide Ltd, H2 2014 81 Assessment by Monotherapy Products, H2 2014 82 Assessment by Combination Products, H2 2014 83 Number of Products by Stage and Target, H2 2014 86 Number of Products by Stage and Mechanism of Action, H2 2014 88 Number of Products by Stage and Route of Administration, H2 2014 90 Number of Products by Stage and Molecule Type, H2 2014 93 Respiratory Syncytial Virus (RSV) Infections Therapeutics - Recent Pipeline Updates, H2 2014 191 Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H2 2014 207 Respiratory Syncytial Virus (RSV) Infections - Discontinued Products, H2 2014 208
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
